Surgery, Urologic Diseases
Conditions
Keywords
UPJ obstruction, pediatric urology, pyeloplasty
Brief summary
This study aimed to evaluate the clinical efficacy of laparoscopic pyeloplasty (LP) for ureteropelvic junction obstruction (UPJO) via retroperitoneal and transperitoneal approaches.
Detailed description
Ureteropelvic junction obstruction (UPJO) is the most common congenital abnormality of the kidney and is responsible for flank pain, recurrent urinary infections, hydronephrosis and the loss of renal function. Until recently, open pyeloplasty (OP) was the standard surgical treatment modality for UPJO.However, with the development of laparoscopic devices and surgical technology, laparoscopic pyeloplasty (LP) has become a more beneficial choice for the patients with UPJO than open surgery because of the advantages of excellent visualization, minimal trauma, rapid postoperative recovery, good cosmetic result, and a nearly successful rate compared with open pyeloplasty. The first LP in children was performed in 1995. It has gained popularity for older children. LP can be performed though retroperitoneal and transperitoneal approaches. Which surgical method is better is still controversial.
Interventions
PROCEDURELaparoscopic pyeloplasty
Twenty patients presented with ureteropelvic junction obstruction \[UPJO\] will be divided into two equal groups. The first was subjected to trans-peritoneal pyeloplasty while the second was subjected to retroperitoneal pyeloplasty.
Sponsors
Assiut University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 18 Years
Inclusion criteria
* Age above two years. * Unilateral UPJO.
Exclusion criteria
* Age below two years. * Bilateral UPJO. * Recurrent UPJO. * Malrotated kidneys and renal fusion anomalies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Operative time | From April 1, 2023 to April 1, 2024 | Operative time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Convergence rate | From April 1, 2023 to April 1, 2024 | Convergence to open pyeloplasty |
| Post operative complications | From April 1, 2023 to April 1, 2024 | Post operative complications |
| Hospital stay | From April 1, 2023 to April 1, 2024 | Hospital stay |
Outcome results
None listed